UK markets closed

Oncimmune Holdings Plc (ONC.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
22.30-1.00 (-4.29%)
At close: 04:05PM GMT

Oncimmune Holdings Plc

1 Park Row
Leeds LS1 5AB
United Kingdom

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Martin John GouldstoneCEO & DirectorN/AN/A1966
Mr. Martin HudsonFinance DirectorN/AN/AN/A
Mr. Ron KirschnerCOO, General Counsel & Company SecretaryN/AN/A1979
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCPChief Scientific OfficerN/AN/AN/A
Ms. Cléa RosenfeldHead of Investor RelationsN/AN/AN/A
Mr. Maarten BrusseChief Commercial Officer of AsiaN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Corporate governance

Oncimmune Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.